These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11125673)

  • 21. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
    Berg BJ; Pettinati HM; Volpicelli JR
    Drug Saf; 1996 Oct; 15(4):274-82. PubMed ID: 8905252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone in patients with bipolar disorder and alcohol dependence.
    Brown ES; Beard L; Dobbs L; Rush AJ
    Depress Anxiety; 2006; 23(8):492-5. PubMed ID: 16841344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers.
    Sandman CA; Hetrick W; Taylor DV; Chicz-DeMet A
    Am J Ment Retard; 1997 Sep; 102(2):182-99. PubMed ID: 9327093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone and dysphoria: fact or myth?
    Miotto K; McCann M; Basch J; Rawson R; Ling W
    Am J Addict; 2002; 11(2):151-60. PubMed ID: 12028745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist.
    Metze D; Reimann S; Luger TA
    Ann N Y Acad Sci; 1999 Oct; 885():430-2. PubMed ID: 10816681
    [No Abstract]   [Full Text] [Related]  

  • 26. Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults.
    Buzan RD; Dubovsky SL; Treadway JT; Thomas M
    Psychiatr Serv; 1995 May; 46(5):511-2. PubMed ID: 7627682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of naltrexone on autistic behavior.
    Zingarelli G; Ellman G; Hom A; Wymore M; Heidorn S; Chicz-DeMet A
    Am J Ment Retard; 1992 Jul; 97(1):57-63. PubMed ID: 1497864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of proopiomelanocortin (POMC) in sequentially dependent self-injurious behavior.
    Sandman CA; Touchette PE; Marion SD; Chicz-DeMet A
    Dev Psychobiol; 2008 Nov; 50(7):680-9. PubMed ID: 18688808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Impulsive behaviors in opiate-dependent subjects treated with naltrexone].
    Pérez de los Cobos J; Pinet C; Ribalta E; Trujols J; Casas M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1994; 22(6):254-60. PubMed ID: 7887206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone has no hepatotoxic effects in a self-injurious patient with chronic hepatitis.
    Hetrick WP; Krutzik MN; Taylor DV; Sandman CA; Rusu L; Martinazzi VP
    J Clin Psychopharmacol; 1993 Dec; 13(6):453-4. PubMed ID: 8120161
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of naltrexone upon self-injurious behavior, learning and activity: a case study.
    Taylor DV; Hetrick WP; Neri CL; Touchette P; Barron JL; Sandman CA
    Pharmacol Biochem Behav; 1991 Sep; 40(1):79-82. PubMed ID: 1780350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone treatment of self-injurious thoughts and behaviors.
    Sonne S; Rubey R; Brady K; Malcolm R; Morris T
    J Nerv Ment Dis; 1996 Mar; 184(3):192-5. PubMed ID: 8600226
    [No Abstract]   [Full Text] [Related]  

  • 33. Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury.
    Sandman CA; Hetrick W; Talyor D; Marion S; Chicz-DeMet A
    Peptides; 2000 Jun; 21(6):785-91. PubMed ID: 10958998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of dissociative symptoms in borderline personality disorder with naltrexone: supplementary comments].
    Schmahl C; Bohus M
    Nervenarzt; 2000 May; 71(5):427. PubMed ID: 10846724
    [No Abstract]   [Full Text] [Related]  

  • 35. Case study: paradoxical response to naltrexone treatment of self-injurious behavior.
    Benjamin S; Seek A; Tresise L; Price E; Gagnon M
    J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):238-42. PubMed ID: 7896657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained-release opiate blockers for treating heroin and amphetamine dependence.
    Penetar DM
    Am J Psychiatry; 2012 May; 169(5):455-7. PubMed ID: 22549204
    [No Abstract]   [Full Text] [Related]  

  • 37. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.
    Miotto K; McCann MJ; Rawson RA; Frosch D; Ling W
    Drug Alcohol Depend; 1997 Apr; 45(1-2):131-4. PubMed ID: 9179515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preventive therapy of opiate addiction with naltrexone].
    Sivolap IuP; Savchenkov VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(11):22-5. PubMed ID: 9845936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of naltrexone on mannerisms and water imbalance in polydipsic schizophrenics: a pilot study.
    Becker JA; Goldman MB; Alam MY; Luchins DJ
    Schizophr Res; 1995 Nov; 17(3):279-82. PubMed ID: 8664207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
    Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
    Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.